logo

Home

Prescribing Info

Mounjaro® (tirzepatide) Injection

The First1 and Only2 GIP and GLP-1
Receptor Agonist Approved for
Obesity Management And

Type 2 Diabetes Management

heroImage
star

INDICATION3

Mounjaro® is a glucose-dependent insulinotropic polypeptide (GIP) and a glucagon-like peptide-1 (GLP-1) receptor agonist.

Mounjaro® is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.

Mounjaro® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including

weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of

• ≥30 kg/m² (obesity) or

• ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension,dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

References

1- Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body Weight Reductions. Cardiovascular diabetology. 2022 Sep 1;21(1):169.

2- GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND DUALAGONISTS. Available at: https://elsevier.health/en-US/preview/glucagon-like-peptide-1-glp-1-receptor-agonists. Last accessed: Nov.05.2024.

3- Mounjaro Egyptian Drug Authority Leaflet. Approval date: 13/3/2024